Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Kymera Therapeutics, Inc. (KYMR : NSDQ)
 
 • Company Description   
Kymera Therapeutics Inc. is a biopharmaceutical company. It is focused on discovering and developing small molecule therapeutics for degrade dysregulated, disease-causing proteins to address previously intractable disease targets. Kymera Therapeutics Inc. is based in Watertown, United States.

Number of Employees: 188

 
 • Price / Volume Information   
Yesterday's Closing Price: $29.11 Daily Weekly Monthly
20 Day Moving Average: 728,838 shares
Shares Outstanding: 65.12 (millions)
Market Capitalization: $1,895.57 (millions)
Beta: 2.18
52 Week High: $53.27
52 Week Low: $19.45
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 21.55% 17.78%
12 Week -17.18% -11.00%
Year To Date -27.64% -24.42%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
500 North Beacon Street 4th Floor
-
Watertown,MA 02472
USA
ph: 857-285-5300
fax: -
investors@kymeratx.com http://www.kymeratx.com
 
 • General Corporate Information   
Officers
Nello Mainolfi - Chief Executive Officer and President
Bruce Booth - Chair of the Board of Directors
Bruce Jacobs - Chief Financial Officer
Felix Baker - Director
Jeff Albers - Director

Peer Information
Kymera Therapeutics, Inc. (CORR.)
Kymera Therapeutics, Inc. (RSPI)
Kymera Therapeutics, Inc. (CGXP)
Kymera Therapeutics, Inc. (BGEN)
Kymera Therapeutics, Inc. (GTBP)
Kymera Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 501575104
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 12/01/24
Next Expected EPS Date: 05/09/25
Share - Related Items
Shares Outstanding: 65.12
Most Recent Split Date: (:1)
Beta: 2.18
Market Capitalization: $1,895.57 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.95 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-3.76 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 11.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 05/09/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.26
Price/Cash Flow: -
Price / Sales: 40.27
EPS Growth
vs. Year Ago Period: -252.00%
vs. Previous Quarter: -7.32%
Sales Growth
vs. Year Ago Period: -84.56%
vs. Previous Quarter: 97.65%
ROE
03/31/25 - -
12/31/24 - -28.66
09/30/24 - -24.96
ROA
03/31/25 - -
12/31/24 - -24.15
09/30/24 - -20.27
Current Ratio
03/31/25 - -
12/31/24 - 7.53
09/30/24 - 8.55
Quick Ratio
03/31/25 - -
12/31/24 - 7.53
09/30/24 - 8.55
Operating Margin
03/31/25 - -
12/31/24 - -475.57
09/30/24 - -191.26
Net Margin
03/31/25 - -
12/31/24 - -475.57
09/30/24 - -191.26
Pre-Tax Margin
03/31/25 - -
12/31/24 - -475.57
09/30/24 - -191.26
Book Value
03/31/25 - -
12/31/24 - 12.90
09/30/24 - 13.79
Inventory Turnover
03/31/25 - -
12/31/24 - -
09/30/24 - -
Debt-to-Equity
03/31/25 - -
12/31/24 - 0.00
09/30/24 - 0.00
Debt-to-Capital
03/31/25 - -
12/31/24 - 0.27
09/30/24 - 0.19
 

Powered by Zacks Investment Research ©